Last deal

Amount

Seed

Stage

25.05.2017

Date

1

all rounds

date founded

Financing round

General

About Company
Proteorex Therapeutics is a biotechnology company focused on discovering and developing novel therapeutics for diseases.

Industry

Sector :

Subsector :

founded date

01.04.2014

Number of employees

Company Type

For Profit

Last funding type

Seed

IPO status

Private

Description

The company utilizes a small-molecule drug discovery platform that integrates a unique synthesis design strategy, computational modeling, and patient-derived cell-based screening. This approach allows them to unlock previously undruggable targets and develop oncology drugs by leveraging protein-protein interactions (PPIs) between chemical molecule peptides. With headquarters in Toronto and an office in San Francisco, Proteorex Therapeutics aims to push the boundaries of drug discovery through innovative and world-class science, addressing diseases with the highest unmet need.
Contacts

Social url

Similar Companies
1000
KSQ Therapeutics

KSQ Therapeutics

KSQ Therapeutics pioneers High-Confidence Drug Development using CRISPRomics technology.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cambridge, MA, USA

total rounds

2

total raised

$156M
Tegmine Therapeutics

Tegmine Therapeutics

Tegmine Therapeutics develops antibody-based therapeutics targeting proteins and their disease-related glycan modifications.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

San Francisco, CA, USA

total rounds

1
Biolexis Therapeutics

Biolexis Therapeutics

Biolexis Therapeutics is a company that uses its FIELDS™ technology to rapidly develop new drugs and accelerate the drug discovery process.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Sandy, UT, USA

total rounds

3

total raised

$12.23M
NextRNA Therapeutics

NextRNA Therapeutics

NextRNA Therapeutics discovers targeted therapeutics by identifying and modulating RNA binding proteins responsible for disease..

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Therapeutics, Pharmaceuticals

Location

Cambridge, MA, USA

total rounds

2

total raised

$56.1M

Financials

Funding Rounds
1
1

Number of Funding Rounds

Their latest funding was raised on 25.05.2017. Their latest investor IndieBio. Their latest round Seed

Date 
Funding Round 
Investors 
Money Raised 
Lead 
25.05.2017
2
IndieBio

IndieBio

IndieBio is a biotechnology and life science startup accelerator that focuses on solving global problems using biology.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Francisco, CA, USA

total rounds

1

total raised

$25M

count Of Investments

493

count Of Exists

7
SOSV

SOSV

SOSV is a global venture capital firm that supports early-stage startups.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital

Location

Princeton, NJ, USA

count Of Investments

2641

count Of Exists

91
Co-Investors
Investors
2
2

Number of lead investors

2

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Seed
IndieBio

IndieBio

IndieBio is a biotechnology and life science startup accelerator that focuses on solving global problems using biology.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Francisco, CA, USA

total rounds

1

total raised

$25M

count Of Investments

493

count Of Exists

7
SOSV

SOSV

SOSV is a global venture capital firm that supports early-stage startups.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital

Location

Princeton, NJ, USA

count Of Investments

2641

count Of Exists

91
Arvind Gupta

Arvind Gupta

Arvind Gupta co-leads Mayfield’s Engineering Biology practice. He was the first investor in breakout bio companies such as Geltor, Synthex, Prime Roots, NotCo, Prellis, New Culture, DNA Lite and Memphis Meats. As Founder of IndieBio, Arvind redefined the pace and possibilities of early stage biotech, investing in over 136 companies in five years, defining human and planetary health, and growing the IndieBio portfolio into billions of dollars in value. Under his leadership, IndieBio expanded to New York and grew to fifteen investment professionals with a world class adjunct partner board. He is now Venture Advisor at IndieBio. Arvind is the author of Decoding the World: A Roadmap for the Questioner, published by Twelve Books, a division of the Hachette Publishing Group. He was honored with the F50 Global Award for Impact in HealthTech Innovation. He is a frequent speaker at TechCrunch Disrupt, Slush, TedX and Future FoodTech. His work has been profiled in global media outlets such as Bloomberg News, Forbes, The Guardian UK, Neo.life, Nikkei News, Rotman, The Times of India, and CGTN in China. Arvind has been a guest lecturer at UCSF, MIT and Harvard and is a judge at the annual BIO conference startup stadium. Prior to founding IndieBio, Arvind was Design Director at IDEO in Shanghai where he earned numerous international design awards and presented his work at the San Francisco Museum of Modern Art. Arvind received his B.S. in Genetic Engineering from UCSB. He holds 8 patents. Arvind is married to an Icelander and has two daughters.

current job

SOSV
SOSV

organization founded

1

People

Founders
2
Michael Anstey
Michael Anstey

Michael Anstey

Michael Anstey is an Investment Director specialising in healthcare investments. Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group’s (BCG) Toronto office. Michael has experience in advising multinational healthcare businesses across North America, Europe, India, and Japan on a broad range of topics, including corporate strategy, sales and marketing, new launches, R&D and medical strategy, and M&A. Michael was co-founder and COO of an early stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease. Prior to BCG, Michael worked in venture capital, where he focused on investing in early stage healthcare and life science businesses. Michael earned his DPhil in Zoology in the field of neurobiology, jointly supervised by professors at the University of Cambridge and the University of Oxford. Michael sits on the board of Bicycle Therapeutics.

current job

Cambridge Innovation Capital
Cambridge Innovation Capital

organization founded

1

Michael Anstey

Aman Iqbal
Aman Iqbal

Aman Iqbal

Aman Iqbal is the Founding Partner of Vantage Health.

current job

Vantage Health

organization founded

3

Aman Iqbal

Employee Profiles
3
Firhan Malik

Firhan Malik

Manager, Finance & Operations

Aman Iqbal

Aman Iqbal

Co-Founder and Chief Executive Officer

Michael Anstey

Michael Anstey

Co-Founder and Chief Operating Officer

Activity

Recent News
0